Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

NCT00548769 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Formulation A
DRUG: Formulation B
DRUG: Formulation C
DRUG: Formulation D

Sponsor

GlaxoSmithKline